Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Azacitidine/Quizartinib Combo Showcases Early Activity in MDS, MDS/MPN With FLT3 or CBL Mutations

August 5th 2022

The combination of azacitidine and quizartinib produced preliminary responses in patients with myelodysplastic syndrome and myelodysplastic syndrome/myeloproliferative neoplasms whose tumors harbored FLT3 or CBL mutations, according to data from a phase 1/2 trial (NCT04493138).

Dr. Leleu on the Future of Later-Line Therapy in Multiple Myeloma

August 4th 2022

Xavier Leleu, MD, PhD, discusses how the declining prognosis of patients with multiple myeloma correlates with line of therapy and time after diagnosis, highlighting an unmet need for more effective later-line therapies in this population.

Use of Romiplostim in Chronic Immune Thrombocytopenia

August 4th 2022

Considerations for the uptake and use of romiplostim, an injectable thrombopoietin receptor agonist, in immune thrombocytopenia.

Data on Avatrombopag in Chronic ITP

August 4th 2022

A commentary on clinical experience with avatrombopag, another oral TPO-RA, in treating ITP.

Ropeginterferon Alfa-2b Proves to be Efficacious, Safe in Japanese Patients with Polycythemia Vera

August 2nd 2022

Ropeginterferon alfa-2b produced durable complete hematologic responses without phlebotomy and showcased a consistent safety profile in Japanese patients with polycythemia vera, according to findings from a phase 2 study (NCT04182100) presented during the 2022 EHA Congress.

FDA Grants Priority Review to Omidubicel for Blood Cancers Requiring Transplant

August 1st 2022

The FDA has accepted a priority review of a biologics license application for omidubicel as a treatment for patients with blood cancers in need of allogenic hematopoietic stem cell transplant.

Identifying the Role of the Microbiome in HSCT and GVHD

August 1st 2022

Expert panelists review the role of the microbiome in the context of hematopoietic stem cell transplantation and steroid-refractory acute GVHD.

Steroid-Refractory GVHD: Enrolling Patients on Clinical Trials

August 1st 2022

Key opinion leaders highlight the value of clinical trials and share their perspective on enrolling patients in the setting of acute GVHD.

Fixed-Duration Venetoclax/Obinutuzumab Provides Robust PFS Benefit in Untreated CLL

July 29th 2022

Othman Al-Sawaf, MD, discusses the 5-year follow-up data of the phase 3 CLL14 trial and emphasized the importance of fixed-duration treatments in high-risk patients with chronic lymphocytic leukemia.

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

July 28th 2022

Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma, pivotal efficacy and safety data from the phase 3 TRANSFORM trial (NCT03575351) and the phase 2 TRANSCEND-PILOT-017006 study (NCT03483103), and the effect of the approval on academic and community center practice patterns.

A Closer Look at CAR T-Cell Therapy Clinical Trial Design

July 28th 2022

Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.

Clinical Trials Evaluating CAR T-Cell Therapies in Second-Line Treatment of Patients With DLBCL

July 28th 2022

Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.

Sylvester Experts Explain the Most Promising Advances in Cancer Research and Treatment Presented at ASCO 2022

July 28th 2022

Cancer experts at the Sylvester Comprehensive Cancer Center: Annual Oncology Update shared important progress across a wide range of cancers — prostate cancer, breast cancer, colon cancer, and more — that was presented at the American Society of Clinical Oncology 2022 Annual Meeting, the largest gathering of cancer clinicians and scientists in the United States.

Eltrombopag in Chronic Immune Thrombocytopenia

July 28th 2022

Expert panelists consider clinical trial data on and personal experience with using eltrombopag, an oral TPO-RA, in immune thrombocytopenia.

Selecting an Oral TPO-RA for Chronic Immune Thrombocytopenia

July 28th 2022

A brief discussion of factors that influence selection of oral versus injectable TPO-RA therapy for ITP.

Ibrutinib Plus Obinutuzumab Elicits Intriguing Survival Benefits in Relapsed/Refractory CLL

July 27th 2022

Christine Ryan, MD, discussed the evaluation of safety and efficacy of ibrutinib plus obinutuzumab in patients with relapsed/refractory CLL in the trial and how the results could result in another treatment option for patients with relapsed/refractory CLL.

Zilovertamab/Ibrutinib Combo Under Exploration to Fill Unmet Need in Relapsed/Refractory MCL

July 26th 2022

The addition of zilovertamab to ibrutinib will be compared with ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma as part of the phase 3 ZILO-301 trial.

Belantamab Mafodotin/Pembrolizumab Combo Elicits Favorable ORR in Heavily Pretreated Multiple Myeloma

July 26th 2022

The addition of pembrolizumab to belantamab mafodotin resulted in a higher overall response rate in patients with relapsed/refractory multiple myeloma than what has been observed with the antibody-drug conjugate alone, according to results from the phase 1/2 DREAMM-4 trial.

New Approvals Help Fill Unmet Need in Treating Chronic GVHD

July 26th 2022

A panel of hematology experts discuss use of steroids in the first-line setting as well as several subsequent-line treatments that have recently received FDA approval for patients with steroid-refractory chronic GVHD, which affects up to 50% of patients.

Overview of Therapy for Steroid-Refractory Acute Graft Versus Host Disease

July 25th 2022

Comprehensive discussion on the treatment options available for patients diagnosed with steroid-refractory acute GVHD.